Company: M’s Science Corporation
Drug Type: Small Molecule
Conditions: Parkinson’s disease
Mechanism Type: Sigma-1 receptor (S1R) agonist
Mechanism: MC116 is a sigma-1 receptor (S1R) agonist, which is being developed for Parkinson’s disease. This is a potentially interesting compound for ALS, since S1R mutations are associated with juvenile ALS, and mouse studies suggest S1R agonists may have therapeutic benefit in ALS.
U.S. Status for ALS: N/A
 M’s Science Corporation. Pipeline. Pipeline. M’s Science Corporation, 2015. Accessed 9 Mar 2016 from http://www.m-sci.com/e/pipeline/cutamesine.html
 A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Al-Saif, A et al. Ann Neurol. 2011 Dec;70(6):913-9.
 Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS). Mavlyutov, TA et al. J Pharmacol Sci. 2015 Jan; 127(1): 10–16.
 Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.
Last updated March 9th, 2016